BeOne Medicines Delivers Quarterly Profit but Revenue Guidance Tests Investor Conviction

BeOne Medicines AG (ONC) reports first-quarter 2026 earnings before market open on May 6, 2026, with investors focused on whether the biotechnology company can rebound from a disappointing fourth quarter that saw a rare miss. The central question: can ONC's oncology portfolio—anchored by BRUKINSA and TEVIMBRA—deliver the growth trajectory analysts expect after last quarter's -63.75% earnings surprise rattled confidence in the company's near-term execution.

Part 1: Earnings Preview

BeOne Medicines AG is a global oncology company focused on discovering and developing treatments for cancer patients, with a commercial portfolio led by BRUKINSA (a BTK inhibitor for blood cancers) and TEVIMBRA (an anti-PD-1 immunotherapy), alongside a deep clinical pipeline spanning solid tumors and hematologic malignancies. The company operates across the United States, China, Europe, and international markets.

For the first quarter ending March 2026, analysts expect ONC to report earnings per share of $0.73, down sharply from the $1.22 reported in the same quarter last year—a -40.16% year-over-year decline. The most recently reported quarter (Q4 2025) delivered EPS of $0.58, missing the $1.60 estimate by -63.75% and marking a significant stumbling block after three consecutive quarters of strong beats.

Three key themes define this earnings story:

1. Recovery from Q4's Execution Miss: The fourth quarter's dramatic shortfall—ONC's first significant miss in over a year—has investors questioning whether operational challenges are temporary or signal deeper issues with commercial execution or clinical trial timelines. Management's ability to explain the Q4 disappointment and demonstrate Q1 represents a return to form will be critical.

2. BRUKINSA Commercial Momentum: As ONC's flagship asset, BRUKINSA's performance in blood cancer indications drives revenue expectations. Analysts are watching for market share gains in BTK inhibitor competition, particularly against established rivals, and any updates on label expansions or new indication approvals that could accelerate growth.

3. Pipeline Progress and Clinical Milestones: With over a dozen clinical-stage programs including Sonrotoclax (Bcl-2 inhibitor), Zanidatamab (HER2 bispecific), and multiple ADCs and bispecifics, investors want visibility on trial readouts, regulatory submissions, and partnership developments that validate ONC's long-term growth story beyond current commercial products.

Ahead of the release, Wall Street sentiment remains cautiously optimistic despite recent volatility. Jefferies downgraded ONC to Hold on March 16, lowering its price target from $420 to $290, citing near-term execution concerns following the Q4 miss. However, the broader analyst community maintains a bullish stance with 15 Strong Buy ratings and a consensus price target of $394.67, suggesting confidence in the company's underlying fundamentals and pipeline potential remains intact despite the recent setback.

Part 2: Historical Earnings Performance

BeOne Medicines has established a pattern of consistently exceeding analyst expectations—until the most recent quarter disrupted that trend. Over the four quarters shown, ONC delivered three consecutive strong beats with surprises of +271.83% (Q1 2025), +75.00% (Q2 2025), and +51.39% (Q3 2025), demonstrating the company's ability to outperform conservative Wall Street estimates by substantial margins.

The magnitude of these beats was particularly impressive in the first half of 2025, with Q1's nearly triple-digit surprise reflecting either significant operational upside or overly cautious analyst modeling. The sequential moderation from +271.83% to +75.00% to +51.39% suggested analysts were gradually recalibrating their models upward to reflect ONC's improving execution.

However, Q4 2025 marked a sharp reversal with a -63.75% miss, reporting $0.58 against a $1.60 estimate. This dramatic shortfall—ONC's first significant miss in the period shown—raises questions about whether the company encountered temporary headwinds or faces more persistent challenges. The upcoming Q1 2026 report will be critical in determining whether Q4 was an anomaly or signals a shift in the company's earnings trajectory.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

BeOne Medicines typically reports earnings before market open, meaning Day 0 captures the market's immediate reaction during the first trading session after results are released, while Day +1 reflects follow-through momentum.

ONC exhibits significant volatility around earnings releases, with an average absolute Day 0 move of 4.66% and intraday range of 6.73%. The stock's post-earnings behavior has been directionally mixed, with four positive Day 0 reactions and four negative ones across the eight quarters shown, suggesting results and guidance—rather than systematic bias—drive the immediate response.

The most extreme moves occurred in recent quarters: February 2026 saw an -8.48% Day 0 decline (the Q4 miss), while February 2025 delivered a +7.48% surge. Day +1 follow-through averages 2.06% in absolute terms with a 3.35% range, indicating continued volatility into the second session as investors digest the full implications of results and management commentary. Investors should prepare for potential swings of 5-9% on earnings day based on historical patterns, with the magnitude likely amplified if ONC either confirms Q4 was an aberration or signals ongoing challenges.

Part 2.2: Options Market Expected Move

The options market is pricing a 2.14% expected move for the May 15 expiration (10 days out), significantly below ONC's historical average Day 0 earnings move of 4.66%. This suggests options traders are either anticipating a more muted reaction than history would indicate, or the May expiration's distance from the May 6 earnings date is dampening implied volatility—investors using options for earnings exposure should consider this disconnect when sizing positions.

Part 3: What Analysts Are Saying

Analyst sentiment on BeOne Medicines remains decidedly bullish despite recent execution concerns, with a consensus rating of 4.72 out of 5.0—firmly in Strong Buy territory. The analyst community shows 15 Strong Buy ratings, 1 Moderate Buy, and 2 Hold ratings, with zero sell recommendations, reflecting confidence in ONC's long-term oncology franchise even as near-term questions persist.

The average price target of $394.67 implies 32.7% upside from the current price of $297.49, with estimates ranging from a low of $333.00 to a high of $430.00. This wide range—nearly $100 between the low and high targets—reflects divergent views on how quickly ONC can resolve its Q4 stumble and return to the growth trajectory that characterized most of 2025.

Sentiment has remained unchanged over the past month, with rating counts and the average recommendation holding steady at 4.72. This stability suggests analysts are taking a wait-and-see approach rather than rushing to revise views ahead of Q1 results—the upcoming report will likely be the catalyst that either validates the bullish consensus or forces downgrades if execution concerns persist. The fact that no analysts have moved to sell ratings despite the Q4 disappointment indicates the Street views ONC's pipeline and commercial assets as fundamentally sound, with recent weakness representing a temporary setback rather than a structural problem.

Part 4: Technical Picture

BeOne Medicines enters earnings in a deteriorating technical position, with the Barchart Technical Opinion showing an 80% Sell signal—up from 72% Sell last week and 56% Sell last month. This progressive weakening reflects mounting downside pressure as the stock has failed to hold key support levels heading into the May 6 report.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, though not at extreme levels
• Medium-term (100% Sell): Strong sell signal across all medium-term indicators suggests the intermediate trend has decisively broken down
• Long-term (100% Sell): Unanimous sell reading reflects significant weakness in the longer-term trend structure

Trend Characteristics: The combination of Average strength and Average direction suggests ONC is experiencing a typical corrective phase rather than an extreme breakdown, though the consistency of selling pressure across timeframes indicates the path of least resistance remains lower absent a catalyst.

The stock is trading at $297.49, below all major moving averages except the 5-day ($294.91). ONC sits below its 10-day ($298.46), 20-day ($306.52), 50-day ($301.78), 100-day ($317.76), and 200-day ($320.59) moving averages, with the 200-day representing overhead resistance nearly 8% above current levels.

The technical setup heading into earnings is cautionary, with ONC trapped below a cluster of resistance levels and showing no signs of stabilization. The stock's inability to reclaim even its 10-day moving average suggests weak hands are exiting ahead of the report, while the 20-day at $306.52 represents the first meaningful resistance level bulls would need to recapture to signal a trend reversal. Given the bearish technical backdrop and the 2.14% options-implied move that understates historical volatility, traders should be prepared for an outsized reaction—particularly if results disappoint again and confirm the Q4 miss was not an isolated event.